Hariharan, S., Israni, A. K. & Danovitch, G. Long-term survival after kidney transplantation. N. Engl. J. Med. 385, 729–743 (2021).
Article CAS PubMed Google Scholar
Himmelfarb, J., Vanholder, R., Mehrotra, R. & Tonelli, M. The current and future landscape of dialysis. Nat. Rev. Nephrol. 16, 573–585 (2020).
Article PubMed PubMed Central Google Scholar
Thurlow, J. S. et al. Global epidemiology of end-stage kidney disease and disparities in kidney replacement therapy. Am. J. Nephrol. 52, 98–107 (2021).
Harris, D. C. H. et al. Increasing access to integrated ESKD care as part of universal health coverage. Kidney Int. 95, S1–S33 (2019).
Francis, A. et al. Chronic kidney disease and the global public health agenda: an international consensus. Nat. Rev. Nephrol. 20, 473–485 (2024).
Liyanage, T. et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 385, 1975–1982 (2015).
Lunney, M. et al. Availability, accessibility, and quality of conservative kidney management worldwide. Clin. J. Am. Soc. Nephrol. 16, 79–87 (2021).
Kaur, G. et al. Cost of hemodialysis in a public sector tertiary hospital of India. Clin. Kidney J. 11, 726–733 (2018).
Article PubMed PubMed Central Google Scholar
Ashuntantang, G. et al. Outcomes in adults and children with end-stage kidney disease requiring dialysis in sub-Saharan Africa: a systematic review. Lancet Glob. Health 5, e408–e417 (2017).
Olowu, W. A. et al. Outcomes of acute kidney injury in children and adults in sub-Saharan Africa: a systematic review. Lancet Glob. Health 4, e242–e250 (2016).
Jamison, D. T. et al. Disease Control Priorities: Improving Health and Reducing Poverty. 3rd edn Vol. 9 (World Bank, 2017); https://doi.org/10.1596/978-1-4648-0527-1.
Teerawattananon, Y., Dabak, S. V., Khoe, L. C., Bayani, D. B. S. & Isaranuwatchai, W. To include or not include: renal dialysis policy in the era of universal health coverage. BMJ 368, m82 (2020).
Article PubMed PubMed Central Google Scholar
Luyckx, V. A., Miljeteig, I., Ejigu, A. M. & Moosa, M. R. Ethical challenges in the provision of dialysis in resource-constrained environments. Semin. Nephrol. 37, 273–286 (2017).
Okpechi, I. G. et al. Building optimal and sustainable kidney care in low resource settings: the role of healthcare systems. Nephrology 26, 948–960 (2021).
Katz, I. J., Gerntholtz, T. & Naicker, S. Africa and nephrology: the forgotten continent. Nephron Clin. Pract. 117, 320–327 (2010).
Van Biesen, W. et al. Considerations on equity in management of end-stage kidney disease in low- and middle-income countries. Kidney Int. Suppl. 10, e63–e71 (2020).
Drummond, M. F., Sculpher, M. J., Claxton, K., Stoddart, G. L., Torrance, G. W. Methods for the Economic Evaluation of Health Care Programmes. Oxford Univ. Press2015.
World Health Organization. 2015 Global Survey on Health Technology Assessment by National Authorities: Main Findings. https://iris.who.int/bitstream/handle/10665/375063/9789241509749-eng.pdf?sequence=1 (2015).
Kim, D. D. et al. Developing criteria for health economic quality evaluation tool. Value Health 26, 1225–1234 (2023).
Caro, J. J., Briggs, A. H., Siebert, U. & Kuntz, K. M. Modeling good research practices — overview: a report of the ISPOR-SMDM modeling good research practices task force-1. Value Health 15, 796–803 (2012).
Edwards, R. T. & McIntosh, E. (eds). Applied Health Economics for Public Health Practice and Research (Oxford Univ. Press, 2019); https://doi.org/10.1093/med/9780198737483.001.0001.
Meltzer, M. I. Introduction to health economics for physicians. Lancet 358, 993–998 (2001).
Article CAS PubMed Google Scholar
Roberts, M. et al. Conceptualizing a model: a report of the ISPOR-SMDM modeling good research practices task force-2. Value Health 15, 804–811 (2012).
Article PubMed PubMed Central Google Scholar
Davies, M. & Cassimjee, Z. Provision of long-term renal replacement therapy to non-national patients in South Africa. South. Afr. Med. J. 111, 615 (2021).
Thaweethamcharoen, T., Sritippayawan, S., Noparatayaporn, P. & Aiyasanon, N. Cost-utility analysis of continuous ambulatory peritoneal dialysis and automated peritoneal dialysis for Thai patients with end-stage renal disease. Value Health Reg. Issues 21, 181–187 (2020).
Bayani, D. B. S. et al. Filtering for the best policy: an economic evaluation of policy options for kidney replacement coverage in the Philippines. Nephrology 26, 170–177 (2021).
Li, B. et al. Equity–efficiency trade-offs associated with alternative approaches to deceased donor kidney allocation: a patient-level simulation. Transplantation 104, 795–803 (2020).
Article PubMed PubMed Central Google Scholar
Spinowitz, B. et al. Economic and quality of life burden of anemia on patients with CKD on dialysis: a systematic review. J. Med. Econ. 22, 593–604 (2019).
Gupta, D. et al. Peritoneal dialysis — first initiative in India: a cost-effectiveness analysis. Clin. Kidney J. 15, 128–135 (2022).
Erbe, A. W., Kendzia, D., Busink, E., Carroll, S. & Aas, E. Value of an integrated home dialysis model in the United Kingdom: a cost-effectiveness analysis. Value Health 26, 984–994 (2023).
Chalkidou, K., Culyer, A. J. & Nemzoff, C. Perspective in Economic Evaluations of Health Care Interventions in Low- and Middle-Income Countries — One Size Does Not Fit All. https://www.cgdev.org/sites/default/files/perspective-economic-evaluations-healthcare-interventions-low-and-middle-income.pdf (Center for Global Development, 2018).
Sittimart, M. et al. An overview of the perspectives used in health economic evaluations. Cost. Eff. Resour. Alloc.22, 41 (2024).
Article PubMed PubMed Central Google Scholar
Drummond, M. et al. Transferability of economic evaluations across jurisdictions: ISPOR good research practices task force report. Value Health 12, 409–418 (2009).
Sassi, F. Calculating QALYs, comparing QALY and DALY calculations. Health Policy Plan. 21, 402–408 (2006).
Donnelly, J. Comparative effectiveness research (updated). Health Aff. (Millwood) https://doi.org/10.1377/hpb20101008.552571 (2010).
Rand, L. Z. & Kesselheim, A. S. Controversy over using quality-adjusted life-years in cost-effectiveness analyses: a systematic literature review. Health Aff. 40, 1402–1410 (2021).
Beresniak, A. et al. Validation of the underlying assumptions of the quality-adjusted life-years outcome: results from the ECHOUTCOME European project. Pharmacoeconomics 33, 61–69 (2015).
Anand, S. & Hanson, K. Disability-adjusted life years: a critical review. J. Health Econ. 16, 685–702 (1997).
Article CAS PubMed Google Scholar
Tomeny, E. M. et al. Rethinking tuberculosis morbidity quantification: a systematic review and critical appraisal of TB disability weights in cost-effectiveness analyses. Pharmacoeconomics 42, 1209–1236 (2024).
Article PubMed PubMed Central Google Scholar
Arnesen, T. & Nord, E. The value of DALY life: problems with ethics and validity of disability adjusted life years. BMJ 319, 1423–1425 (1999).
Comments (0)